Working… Menu
Trial record 1 of 1 for:    NCT03415854
Previous Study | Return to List | Next Study

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) (NABPLAGEMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03415854
Recruitment Status : Active, not recruiting
First Posted : January 30, 2018
Last Update Posted : May 28, 2021
Barts Cancer Institute
Abramson Cancer Center of the University of Pennsylvania
Salk Institute for Biological Studies
Mayo Clinic
Princeton University
Imaging Endpoints
Translational Genomics Research Institute
Stand Up To Cancer
Cancer Research UK
Lustgarten Foundation
University of California, San Diego
Information provided by (Responsible Party):
HonorHealth Research Institute

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021